Amytrx Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Amytrx Therapeutics's estimated annual revenue is currently $310k per year.(i)
  • Amytrx Therapeutics's estimated revenue per employee is $77,500

Employee Data

  • Amytrx Therapeutics has 4 Employees.(i)
  • Amytrx Therapeutics grew their employee count by 0% last year.

Amytrx Therapeutics's People

NameTitleEmail/Phone
1
SVP, Research & DevelopmentReveal Email/Phone
2
VP, Chemistry & ManufacturingReveal Email/Phone
3
President & CEO, Co-Founder, DirectorReveal Email/Phone
4
Chief Business OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M110%N/AN/A
#2
$5M3214%N/AN/A
#3
$3.6M235%N/AN/A
#4
$1.1M7-22%N/AN/A
#5
$1.7M110%N/AN/A
#6
$0.8M50%N/AN/A
#7
$6M3950%N/AN/A
#8
$0.9M60%N/AN/A
#9
$4.8M31-6%N/AN/A
#10
$1.9M120%N/AN/A
Add Company

What Is Amytrx Therapeutics?

Amytrx Therapeutics is advancing a new class of peptide therapies to overcome inflammatory diseases—with a vision of providing transformative medicines to patients. Drawing on 25 years of research, Amytrx is harnessing the power of novel anti-inflammatory peptide discoveries to advance new medicines aimed at the prevention and treatment of inflammatory diseases. Our lead therapeutic candidate, AMTX-100, is bioengineered from human protein sequences that modulate the immune system by a natural process, reducing pathogenesis in a range of chronic diseases mediated by excessive inflammation. Joining forces with institutions for clinical research, Amytrx Therapeutics is dedicated to transforming the conventional treatment of chronic inflammatory diseases using biological technology that is easily understood by the human body in a way that is safe, effective, and simple to use.

keywords:N/A

N/A

Total Funding

4

Number of Employees

$310k

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.3M40%N/A
#2
$0.4M40%N/A
#3
$0.5M4-33%N/A
#4
$0.4M4-94%N/A
#5
$0.3M4N/AN/A